Citrus limonin glucoside supplementation decreased biomarkers of liver disease and inflammation in overweight human adults

Darshan S. Kelley, Yuriko C. Adkins, Susan J. Zunino, Leslie R. Woodhouse, Ellen L. Bonnel, Andrew P. Breksa, Gary D. Manners, Bruce E. Mackey

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Mixtures of limonoid glucosides demonstrated health benefits in human and animal studies; however, the specific metabolic effects of purified citrus limonin glucoside (LG) in humans are unknown. We determined effects of LG on circulating biomarkers of chronic inflammatory diseases such as nonalcoholic fatty liver disease (NAFLD), diabetes, CVD, and cancer in a cross-over, placebo controlled, double-blind study in overweight/obese individuals. LG had no specific adverse effects. It did not alter circulating concentrations of blood lipids, lipoproteins or their particle sizes, glucose, insulin, hematological parameters, and markers of inflammation except MMP-9 and TNF-α which were decreased by 38.7% and 10.7%, respectively. LG significantly decreased concentrations of liver proteins: gamma-glutamyl transferase (33.8%), alanine aminotransferase (13.1%), alkaline phosphatase (10.1%), and complement C3 (6.4%). Since liver enzymes are elevated in metabolic syndrome, NAFLD, diabetes, CVD, and chronic kidney disease and liver cancer, LG may be useful in the prevention and/or treatment of those diseases.

Original languageEnglish (US)
Pages (from-to)271-281
Number of pages11
JournalJournal of Functional Foods
Volume12
DOIs
StatePublished - Jan 1 2015

Fingerprint

limonin
Citrus
Glucosides
liver diseases
glucosides
Liver Diseases
biomarkers
inflammation
Biomarkers
Inflammation
fatty liver
diabetes
Limonins
limonoids
liver protein
Complement C3
gelatinase B
gamma-glutamyltransferase
liver neoplasms
Kidney Neoplasms

Keywords

  • Cardiovascular disease
  • Inflammation
  • Liver enzymes
  • Metabolic syndrome
  • Nonalcoholic fatty liver disease
  • Obesity

ASJC Scopus subject areas

  • Food Science
  • Medicine (miscellaneous)
  • Nutrition and Dietetics

Cite this

Kelley, D. S., Adkins, Y. C., Zunino, S. J., Woodhouse, L. R., Bonnel, E. L., Breksa, A. P., ... Mackey, B. E. (2015). Citrus limonin glucoside supplementation decreased biomarkers of liver disease and inflammation in overweight human adults. Journal of Functional Foods, 12, 271-281. https://doi.org/10.1016/j.jff.2014.11.026

Citrus limonin glucoside supplementation decreased biomarkers of liver disease and inflammation in overweight human adults. / Kelley, Darshan S.; Adkins, Yuriko C.; Zunino, Susan J.; Woodhouse, Leslie R.; Bonnel, Ellen L.; Breksa, Andrew P.; Manners, Gary D.; Mackey, Bruce E.

In: Journal of Functional Foods, Vol. 12, 01.01.2015, p. 271-281.

Research output: Contribution to journalArticle

Kelley, DS, Adkins, YC, Zunino, SJ, Woodhouse, LR, Bonnel, EL, Breksa, AP, Manners, GD & Mackey, BE 2015, 'Citrus limonin glucoside supplementation decreased biomarkers of liver disease and inflammation in overweight human adults', Journal of Functional Foods, vol. 12, pp. 271-281. https://doi.org/10.1016/j.jff.2014.11.026
Kelley, Darshan S. ; Adkins, Yuriko C. ; Zunino, Susan J. ; Woodhouse, Leslie R. ; Bonnel, Ellen L. ; Breksa, Andrew P. ; Manners, Gary D. ; Mackey, Bruce E. / Citrus limonin glucoside supplementation decreased biomarkers of liver disease and inflammation in overweight human adults. In: Journal of Functional Foods. 2015 ; Vol. 12. pp. 271-281.
@article{b6f7f8ce8326426dbd513c6d2a0e2282,
title = "Citrus limonin glucoside supplementation decreased biomarkers of liver disease and inflammation in overweight human adults",
abstract = "Mixtures of limonoid glucosides demonstrated health benefits in human and animal studies; however, the specific metabolic effects of purified citrus limonin glucoside (LG) in humans are unknown. We determined effects of LG on circulating biomarkers of chronic inflammatory diseases such as nonalcoholic fatty liver disease (NAFLD), diabetes, CVD, and cancer in a cross-over, placebo controlled, double-blind study in overweight/obese individuals. LG had no specific adverse effects. It did not alter circulating concentrations of blood lipids, lipoproteins or their particle sizes, glucose, insulin, hematological parameters, and markers of inflammation except MMP-9 and TNF-α which were decreased by 38.7{\%} and 10.7{\%}, respectively. LG significantly decreased concentrations of liver proteins: gamma-glutamyl transferase (33.8{\%}), alanine aminotransferase (13.1{\%}), alkaline phosphatase (10.1{\%}), and complement C3 (6.4{\%}). Since liver enzymes are elevated in metabolic syndrome, NAFLD, diabetes, CVD, and chronic kidney disease and liver cancer, LG may be useful in the prevention and/or treatment of those diseases.",
keywords = "Cardiovascular disease, Inflammation, Liver enzymes, Metabolic syndrome, Nonalcoholic fatty liver disease, Obesity",
author = "Kelley, {Darshan S.} and Adkins, {Yuriko C.} and Zunino, {Susan J.} and Woodhouse, {Leslie R.} and Bonnel, {Ellen L.} and Breksa, {Andrew P.} and Manners, {Gary D.} and Mackey, {Bruce E.}",
year = "2015",
month = "1",
day = "1",
doi = "10.1016/j.jff.2014.11.026",
language = "English (US)",
volume = "12",
pages = "271--281",
journal = "Journal of Functional Foods",
issn = "1756-4646",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Citrus limonin glucoside supplementation decreased biomarkers of liver disease and inflammation in overweight human adults

AU - Kelley, Darshan S.

AU - Adkins, Yuriko C.

AU - Zunino, Susan J.

AU - Woodhouse, Leslie R.

AU - Bonnel, Ellen L.

AU - Breksa, Andrew P.

AU - Manners, Gary D.

AU - Mackey, Bruce E.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Mixtures of limonoid glucosides demonstrated health benefits in human and animal studies; however, the specific metabolic effects of purified citrus limonin glucoside (LG) in humans are unknown. We determined effects of LG on circulating biomarkers of chronic inflammatory diseases such as nonalcoholic fatty liver disease (NAFLD), diabetes, CVD, and cancer in a cross-over, placebo controlled, double-blind study in overweight/obese individuals. LG had no specific adverse effects. It did not alter circulating concentrations of blood lipids, lipoproteins or their particle sizes, glucose, insulin, hematological parameters, and markers of inflammation except MMP-9 and TNF-α which were decreased by 38.7% and 10.7%, respectively. LG significantly decreased concentrations of liver proteins: gamma-glutamyl transferase (33.8%), alanine aminotransferase (13.1%), alkaline phosphatase (10.1%), and complement C3 (6.4%). Since liver enzymes are elevated in metabolic syndrome, NAFLD, diabetes, CVD, and chronic kidney disease and liver cancer, LG may be useful in the prevention and/or treatment of those diseases.

AB - Mixtures of limonoid glucosides demonstrated health benefits in human and animal studies; however, the specific metabolic effects of purified citrus limonin glucoside (LG) in humans are unknown. We determined effects of LG on circulating biomarkers of chronic inflammatory diseases such as nonalcoholic fatty liver disease (NAFLD), diabetes, CVD, and cancer in a cross-over, placebo controlled, double-blind study in overweight/obese individuals. LG had no specific adverse effects. It did not alter circulating concentrations of blood lipids, lipoproteins or their particle sizes, glucose, insulin, hematological parameters, and markers of inflammation except MMP-9 and TNF-α which were decreased by 38.7% and 10.7%, respectively. LG significantly decreased concentrations of liver proteins: gamma-glutamyl transferase (33.8%), alanine aminotransferase (13.1%), alkaline phosphatase (10.1%), and complement C3 (6.4%). Since liver enzymes are elevated in metabolic syndrome, NAFLD, diabetes, CVD, and chronic kidney disease and liver cancer, LG may be useful in the prevention and/or treatment of those diseases.

KW - Cardiovascular disease

KW - Inflammation

KW - Liver enzymes

KW - Metabolic syndrome

KW - Nonalcoholic fatty liver disease

KW - Obesity

UR - http://www.scopus.com/inward/record.url?scp=84920718953&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84920718953&partnerID=8YFLogxK

U2 - 10.1016/j.jff.2014.11.026

DO - 10.1016/j.jff.2014.11.026

M3 - Article

AN - SCOPUS:84920718953

VL - 12

SP - 271

EP - 281

JO - Journal of Functional Foods

JF - Journal of Functional Foods

SN - 1756-4646

ER -